An exploratory analysis of alendronate in older men with low glomerular filtration rate

Journal of Aging and Pharmacotherapy

Volumn 13, Issue 2, 2007, Pages 21-33

  Hansen, K E ^a   Hoffman, R M ^a   Drake, R K ^b   Argall, T R ^b   Bier, H A ^b   Grigg, K T ^b   Rouse, E D ^b   Elliott, M E ^b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Bisphosphonate; Bone density; Osteoporosis; Renal osteodystrophy

Indexed keywords

ALENDRONIC ACID;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; AGED; ARTHRALGIA; ARTICLE; BONE MASS; BONE PAIN; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DYSPEPSIA; DYSPHAGIA; ESOPHAGUS ULCER; FEMUR; FLATULENCE; GASTRITIS; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; MALE; MUSCLE CRAMP; MYALGIA; OSTEOPOROSIS; RADIUS; RETROSPECTIVE STUDY; SIDE EFFECT; SPINE; TASTE ACUITY; VOMITING;

EID: 33947095172     PISSN: 15405303     EISSN: 15404706     Source Type: Journal    
DOI: 10.1300/J397v13n02_03     Document Type: Article

References (28)

1. Melton LJ III, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol 1989; 129: 1000-1011.
2. Looker AC, Orwoll ES, Johnston CC Jr., et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997; 12: 1761-1768.
3. Klawansky S, Komaroff E, Cavanaugh PF Jr., et al. Relationship between age, renal function and bone mineral density in the U.S. population. Osteoporos Int 2003; 14: 570-576.
4. Stehman-Breen C. Osteoporosis and chronic kidney disease. Semin Nephrol 1994; 24: 78-81.
5. Torres A, Lorenzo V Hernandez D, et al. Bone diseases in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442.
6. Uribarri J. K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: Some therapeutic implications. Semin Dial 2004; 17: 349-350.
7. Cunningham J, Sprague SM, Cannata-Andia J, et al. Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004; 43: 566-571.
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
9. Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D. Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003; 41: E18.
10. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chateleanat F. Renal failure associated with intravenous diphosphonates. Lancet 1983; 1: 471.
11. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulonephrosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164-1172.
12. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64: 281-289.
13. Chang JT, Green L, Beitz J. Renal failure with the use of zolendronic acid. N Engl J Med 2003; 349: 1676-1679.
14. Lee S, Glicklich D, Coco M. Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction. Neprhol Dial Transplant 294; 19: 2870-2873.
15. Mitchell DY, St Peter JV, Eusebio RA, et al. Effect of renal function on risedronate pharmacokinetics after a single oral dose. Br J Clin Pharmacol 1999; 49: 215-222.
16. Saha H, Castren-Kortekangas P, Ojanen S, et al. Pharmacokinetics of clodronate in renal failure. J Bone Miner Res 1994; 9: 1953-1958.
17. Skerjanec A, Berenson J, Hsu C, et al. The pharmacokinetics and pharmacodynamics of zolendronic acid in patients with cancer with varying degrees of renal function. J Clin Pharmacol 2003; 43: 154-162.
18. Berenson JR, Rosen L, Vescio R, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997; 37: 285-290.
19. Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 1996; 45: 175-179.
20. Miller P, Barton I, Dunlap L, Burgio D. Risedronate treated patients with reduced renal function show no significant increase in renal function-related AEs as compared to placebo. J Bone Miner Res 2993; 18 (Suppl 2): S262.
21. Fan SL, Cunningham J. Bisphosphonates in renal osteodystrophy. Curr Opin Nephrol Hypertens 2001; 10: 581-588.
22. Eyres KS, Marshall P, McCloskey E, Douglas DL, Kanis JA. Spontaneous fractures in a patient treated with low doses of etidronoc acid (disodium etidronate). Drug Saf 1992; 7: 162-165.
23. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 1995; 90: 1294-301.
24. Rodan GA, Seedor JG, Balena R. Preclinical pharmacology of alendronate. Osteoporos Int 1993; 3 (Suppl 3): S7-S12.
25. Khan SA, Kanis JA, Vasikaran S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997; 12: 1700-1707.
26. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001; 16: 113-119.
27. Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: A double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 3319-3325.
28. Coen G, Mazzafero S, Ballanti P, et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study. Nephrol Dial Transplant 1996; 11: 813-819.